## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Serial No.:

10/599,479

Confirmation No.:

9587

Applicant(s):

Masayoshi SHICHIRI

Group Art Unit:

Examiner:

Filed:

Sept. 29, 2006

Customer No.:

27123

For:

Cardioinhibitory/ Antihypertensive Novel Endogenous Physiologically Active Peptide

## INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Pursuant to Rule 56, applicant hereby calls the attention of the Patent Office to the references listed on the attached Form PTO 1449.

Copy(ies) of these references:

Foreign Patent Applications, Foreign Patents and/or Other Non-Patent Documents are attached (Copies of cited U.S. Patents/Publications are not provided).

This document is being filed within three (3) months of the filing date of the application

This document is being filed prior to a first Office Action

The Commissioner is hereby authorized to charge any additional fees which may be required for this Information Disclosure Statement, or credit any overpayment to Deposit Account No. 13-4500, Order No. 4439-4047.

Respectfully submitted,

MORGAN & FINNEGAN, L.L.P.

Dated: November 6, 2006

Evelyn M. Kwor

Registration No. 54,246

Correspondence Address:

MORGAN & FINNEGAN, L.L.P. 3 World Financial Center New York, NY 10281-2101 (212) 415-8700 Telephone (212) 415-8701 Facsimile

#### Attorney Docket: Serial No.: 4439-4047 10/599,479 FORM PTO-1449A Applicant: Masayoshi SHICHIRI INFORMATION DISCLOSURE CITATION Group Art Unit: Filing Date: Sept. 29, 2006 U.S. PATENT / PUBLICATION DOCUMENTS Examiner Filing Initial Patent/Publication Number Publication/Issue Date Date Name 1. 2. 3. 4. 5. 6. 7. 8. 9. 10. 11. 12. 13. 14. FOREIGN PATENT DOCUMENTS Examiner Publication Copy Initial Filed **Patent Number** Date Country Translation 15. WO 01/32875 A1 May 10, 2001 **PCT** ✓ Yes ☐ Yes ☐ No ☐ Abstract ☒N/A 2004-008027 Yes 16. June 6, 2004 ☐ Yes ☐ No ☒ Abstract ☐N/A Japan 17. ☐ Yes ☐ Yes ☐ No ☐ Abstract ☐N/A 18. ☐ Yes ☐ Yes ☐ No ☐ Abstract ☐N/A

Examiner		Date Considered		
EXAMINER:	Initial if reference considered, whether or not citation is in conformance with MPEP §609.  Draw line through citation if not in conformance and not considered.  Include copy of this form with next communication to Applicant.			

☐ Yes

☐ Yes

☐ Yes ☐ No ☐ Abstract ☐ N/A

☐ Yes ☐ No ☐ Abstract ☐ N/A

19.

20.

Page 1 of 1

### **FORM PTO-1449B**

# INFORMATION DISCLOSURE CITATION

Attorney Docket:	Serial No.:	
4439-4047	10/599,479	
Applicant:		
Masayoshi SHICHIRI		
Filing Date:	Group Art Unit:	
Sept. 29, 2006	_	

		NON PATENT LITERATURE DOCUMENTS
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
		MASAYOSHI SHICHIRI et al., Salusins: newly identified bioactive peptides with
	1.	hemodynamic and mitogenic activities, Nature Medicine, September 2003, pp. 1166-1172, Vol. 9, No. 9.
	2.	HUA LOU and ROBERT F. GAGEL, Alternative Ribonucleic Acid Processing in Endocrine Systems, Endocrine Reviews, 2001, pp. 205-225, The Endocrine Society, Vol. 22, No. 2.
	3.	MASAYOSHI SHICHIRI, Salusins, July 7, 2004, pp. 267-270, Vol. 210, No. 4.
		FANG YU et al., Salusins promote cardiomyocyte growth but does not affect cardiac
		function in rats, Regulatory Peptides, published online on August 18, 2004, pp. 191-197, No.
1 TO COMPANY 1 TO THE OWNER OF THE OWNER OW	4.	122, Elsevier.
		HAJIME IZUMIYAMA et al., Synthetic Salusins as Cardiac Depressors in Rat,
	5.	Hypertension, March 2005, pp. 419-425, No. 45, American Heart Association.
Hastistorial data farman romania i i i mana i i	6.	
	7.	
	8.	
	9.	
PAPPAR (PPARA) SAPAK (AUGSEL AUGSEL)	10.	
	11.	
	12.	
	13.	
	14.	
and the second of the second o	15.	
	16.	
·	17.	
and a summer of the party of the state of th	18.	
······································	19.	
	20.	

Examiner	 Date	
Signature	Considered	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.